

Maleimide-functionalised PLGA-PEG nanoparticles as mucoadhesive carriers for intravesical drug delivery

Article

Accepted Version

Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Kaldybekov, D., Filippov, S. K., Radulescu, A. and Khutoryanskiy, V. V. (2019) Maleimide-functionalised PLGA-PEG nanoparticles as mucoadhesive carriers for intravesical drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 143. pp. 24-34. ISSN 0939-6411 doi: https://doi.org/10.1016/j.ejpb.2019.08.007 Available at http://centaur.reading.ac.uk/85583/

It is advisable to refer to the publisher's version if you intend to cite from the work. See <u>Guidance on citing</u>.

To link to this article DOI: http://dx.doi.org/10.1016/j.ejpb.2019.08.007

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the <u>End User Agreement</u>.

www.reading.ac.uk/centaur



CentAUR

Central Archive at the University of Reading

Reading's research outputs online

1	Maleimide-functionalised PLGA-PEG nanoparticles as
2	mucoadhesive carriers for intravesical drug delivery
3	Daulet B. Kaldybekov ^{a,b} , Sergey K. Filippov ^c , Aurel Radulescu ^d , Vitaliy V. Khutoryanskiy ^{a,*}
4	^a School of Pharmacy, University of Reading, Whiteknights, RG6 6AD Reading, United Kingdom
5	^b Department of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, 050040
6	Almaty, Kazakhstan
7	^c Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge,
8	MA 02138, United States
9	^d Forschungszentrum Jülich GmbH, Jülich Centre for Neutron Science (JCNS) at Heinz Maier-Leibnitz
10	Zentrum (MLZ), Lichtenbergstraße 1, 85748 Garching, Germany
11	*Corresponding author
12	Postal address: School of Pharmacy, University of Reading, Whiteknights, PO Box 224, Reading,
13	RG6 6AD, United Kingdom
14	E-mail address: v.khutoryanskiy@reading.ac.uk (V.V. Khutoryanskiy)
15	Phone: +44(0) 118 378 6119
16	Fax: +44(0) 118 378 4703

17 Abstract

18 Low permeability of the urinary bladder epithelium, poor retention of the chemotherapeutic agents due 19 to dilution and periodic urine voiding as well as intermittent catheterisations are the major limitations of 20 intravesical drug delivery used in the treatment of bladder cancer. In this work, maleimide-functionalised 21 poly(lactide-*co*-glycolide)-*block*-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles were 22 developed. Their physicochemical characteristics, including morphology, architecture and molecular 23 parameters have been investigated by means of dynamic light scattering, transmission electron 24 microscopy and small-angle neutron scattering techniques. It was established that the size of 25 nanoparticles was dependent on the solvent used in their preparation and molecular weight of PEG, for 26 example, 105 ± 1 nm and 68 ± 1 nm particles were formed from PLGA_{20K}-PEG_{5K} in dimethyl sulfoxide 27 and acetone, respectively. PLGA-PEG-Mal nanoparticles were explored as mucoadhesive formulations 28 for drug delivery to the urinary bladder. The retention of fluorescein-loaded nanoparticles on freshly 29 excised lamb bladder mucosa in vitro was evaluated and assessed using a flow-through fluorescence 30 technique and Wash Out₅₀ (WO₅₀) quantitative method. PLGA-PEG-Mal nanoparticles (NPs) exhibited 31 greater retention on urinary bladder mucosa ($WO_{50} = 15 \text{ mL}$) compared to maleimide-free NPs ($WO_{50} =$ 32 5 mL). The assessment of the biocompatibility of PEG-Mal using the slug mucosal irritation test revealed 33 that these materials are non-irritant to mucosal surfaces.

Keywords: urinary bladder, intravesical drug delivery, PLGA-PEG, maleimide, nanoparticles, small angle neutron scattering, slug mucosal irritation test, mucoadhesion, Wash Out₅₀ (WO₅₀).

1. Introduction

38 Mucoadhesion can be described as the ability of materials to adhere to mucosal membranes for 39 extended periods of time. Transmucosal drug administration is currently employed in ocular 40 (conjunctival and corneal), nasal, pulmonary, oromucosal (buccal and sublingual), gastrointestinal, 41 rectal, vaginal and intravesical drug delivery, and it offers an alternative to injections [1–6]. 42 Transmucosal drug delivery provides numerous advantages, including (i) prolonged residence time of a 43 dosage form and high density of blood vessels on mucosal surfaces ensure more efficient and rapid drug 44 absorption; (ii) non-oral drug administration allows avoiding its potential degradation in the stomach and 45 prevents hepatic first-pass metabolism; (iii) ease of drug administration and the possibility for quick 46 termination of a therapy resulting in improved patient compliance; (iv) possibility of targeting particular 47 body sites and tissues due to local administration; and (v) reduced administration frequency. 48 Mucoadhesive dosage forms could be highly beneficial for local drug administration to treat posterior 49 segment diseases of the eye [7,8], neurological disorders (via intranasal administration) [9,10], and 50 genitourinary tract dysfunctions [11,12].

Intravesical drug delivery (IDD) refers to a direct administration of active pharmaceutical ingredients into the urinary bladder using a catheter inserted through the urethra. This technique is generally used to treat bladder-related disorders, such as bladder cancer (BC) and interstitial cystitis [13– 15]. However, the efficiency of this route of drug administration is limited due to dilution and wash out during periodical micturition resulting in poor retention of instilled therapeutic agents. Additionally, the need for frequent catheterisations with potential risks of irritation, inflammatory reactions and infections makes this procedure rather unpleasant for patients [16].

58 Mucoadhesive materials have the potential to improve the efficacy of IDD by prolonging the drug 59 residence in the bladder. First generation (conventional) mucoadhesive materials are traditionally used 60 as matrixes in many formulations for transmucosal drug delivery. These include hydrophilic polymers 61 of natural and synthetic origin, such as chitosan, carbopols and cellulose derivatives [17–21]. The

adhesion of these macromolecules is due to their ability to interact with glycosylaminoglycans/mucins
 present on mucosal surfaces through non-covalent interactions such as hydrogen bonding, electrostatic
 attraction and chain entanglement.

65 Andreas Bernkop-Schnürch [22] pioneered the use of thiolated polymers (thiomers) as the second 66 generation of mucoadhesives. Well-established water-soluble polymers were modified with thiol 67 functional groups using different chemical approaches to greatly enhance their mucoadhesive properties 68 [23–25]. A few studies reported the use of thiolated mucoadhesives for IDD. For example, thiol-69 functionalised chitosan nanoparticles have been used for IDD in an *in vitro* study using porcine urinary 70 bladders [26,27]. The ability of these thiolated mucoadhesives to stay adhered on mucosal surfaces is 71 due to the formation of inter-disulphide bridges *via* covalent interaction with cysteine residues present in 72 mucins.

73 Recently, our group has demonstrated that polymeric nanogels [28] and PEGylated liposomes [29] 74 functionalised with maleimide groups exhibited excellent mucoadhesive properties to bovine 75 conjunctival tissues and freshly excised porcine bladder mucosa, respectively. The ability of these 76 formulations to retain on mucosal tissues, evaluated using a flow-through method, was found to be 77 comparable to a well-known mucoadhesive chitosan. The excellent mucoadhesive performance of these 78 novel advanced formulations is attributed to their ability to form covalent linkages with thiol groups 79 present in the mucus via Michael-type addition reactions. Later, other researchers have also reported the 80 development of alginate- and chitosan-based mucoadhesives functionalised with maleimide groups and 81 demonstrated their superior retention/adhesion on/to mucosal surfaces compared to unmodified 82 polysaccharides [30, 31]. All the maleimide-functionalised systems reported so far [28–31] due to their 83 hydrophilic nature were only suitable for formulation of water-soluble drugs. There is also a strong need 84 in the development of mucoadhesive drug delivery systems capable of incorporating poorly-soluble 85 drugs, which will require the use of less polar polymers for their development.

86 Poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG), a block copolymer 87 approved by the US Food and Drug Administration, has been widely employed in controlled release 88 formulations and tissue engineering applications due to its safety, low toxicity, low immunogenicity, 89 high cytocompatibility and biodegradability [32]. PLGA-PEG could easily be self-assembled to micelles 90 or nanoparticles by either simple single emulsion (oil-in-water) or double emulsion solvent evaporation 91 (water/oil/water) techniques [33,34]. For instance, Bazylińska et al. [35] described the influence of 92 preparation parameters, the type of polymer and active cargo on the colloidal and biological stability of 93 final nano-carriers for further in vitro and in vivo applications. Pei et al. developed the application of pH-94 sensitive intravenous PLGA-PEG formulations to deliver vancomycin in the therapy against intracellular 95 pathogens [36]. PLGA-PEG nanoparticles functionalised with maleimide groups were also recently 96 reported as carriers for drug delivery. Their maleimide-functionalised surface was used for further 97 modification with monoclonal antibody [37] and cell penetrating peptides [38].

98 In the present work, we report the design of maleimide-functionalised PLGA-PEG nanoparticles 99 as potential mucoadhesive formulations for IDD to urinary bladder and demonstrate that surface 100 maleimide groups could significantly enhance mucoadhesive properties of these materials. Four types of 101 nanoparticles were developed using PLGA-PEG containing 3 and 5 kDa PEG with and without 102 maleimide terminal groups. The structural features of these nanoparticles were studied using small-angle 103 neutron scattering, dynamic light scattering and transmission electron microscopy. The hydrophobic 104 nature of PLGA-based core of the nanoparticles provided an excellent opportunity for formulating poorly 105 water-soluble compound as a model drug. These nanoparticles were loaded with lipophilic fluorescein 106 and their retention on urinary bladder mucosa was studied in vitro. Slug mucosal irritation in vivo test 107 was used to assess the biocompatibility of PEG-Mal present on the surface of these nanoparticles.

2. Materials and methods

110 **2.1. Materials**

111 Four different di-block copolymers of poly(lactide-*co*-glycolide)-poly(ethylene glycol) ((methoxyterminated: Mw 20,000 : 3,000 Da, PDI 1.30 (PLGA_{20K}-PEG_{3K}) and Mw 20,000 : 5,000 Da, PDI 1.65 112 113 (PLGA_{20K}-PEG_{5K}); maleimide-functionalised: Mw 20,000 : 3,400 Da, PDI 2.70 (PLGA_{20K}-PEG_{3K}-Mal) and Mw 20,000 : 5,000 Da, PDI 2.42 (PLGA_{20K}-PEG_{5K}-Mal)) were purchased from PolySciTech[®] Akina 114 115 Inc. (West Lafayette, IN, USA; catalogue numbers: AK101, AK037, AI109, AI020). Dimethyl sulfoxide 116 (DMSO) was purchased from Fisher Scientific (Loughborough, UK), acetone and deuterium oxide 117 (D₂O), benzalkonium chloride (BAC), poly(ethylene glycol) methyl ether (PEG; average Mn 5,000 Da), 118 methoxypolyethylene glycol maleimide (PEG-Mal; average Mn 5,000 Da) and phosphate buffered saline 119 tablets (PBS) were purchased from Sigma-Aldrich (Gillingham, UK). 6-Maleimidohexanoic acid was 120 purchased from Alfa Aesar (Hevsham, UK). Fluorescein was purchased from Acros Organics (Geel, 121 Belgium). All other chemicals were of analytical grade and used as received.

122

2.2. Preparation of nanoparticles

123 Empty and fluorescein-loaded PLGA-PEG nanoparticles were prepared via one-step 124 nanoprecipitation (single emulsion) technique followed by dialysis. In brief, 20 mg of polymers and 1 125 mg fluorescein were dissolved in 1 mL of DMSO or acetone to form organic phase. The organic phase 126 was then added to 30 mL of deionised water dropwise under constant stirring to form a colloidal 127 suspension, which was allowed to stir gently for 1 h. Finally, this suspension was purified by dialysis 128 against deionised water (5L; 4 changes) using a dialysis membrane tube (molecular weight cut-off 12-129 14 kDa; Medicell Membranes Ltd., UK) to remove residual solvent, filtered using 0.22 µm Minisart® 130 syringe filters and stored in a fridge for further use.

131 **2.3.** Particle size and zeta potential analysis

The size of fluorescein-free PLGA-PEG nanoparticles, their polydispersity index (PDI) and zetapotential values were determined using dynamic light scattering (DLS) at a scattering angle of 173° with a Zetasizer Nano-NS (Malvern Instruments, UK). Each nanoparticle dispersion was diluted 100-fold with ultra-purified water. Refractive index of 1.59 and absorbance of 0.01 were used in all measurements. Each sample was analysed three times at 25 °C and the Z-average mean \pm standard deviation values were calculated.

138

2.4. Transmission electron microscopy (TEM)

139 Nanoparticles were imaged using a JEOL 2100 Plus TEM operated at an acceleration voltage of 140 200 kV. Specimens were prepared by pipetting a drop of purified nanoparticle suspension (about 0.5 141 mg/mL) onto a parafilm. A glow-discharged holey carbon film-coated 400-mesh copper grid was then 142 placed onto the drop with "carbon" side and left in contact with the sample for 60 sec. The excess solution 143 was removed by blotting with a filter paper. Then, a drop of 2% (w/v) uranyl acetate (UA) solution was 144 deposited onto the parafilm and the grid remained in contact with "carbon" side with UA for another 60 145 sec. The excess stain was removed by dabbing similarly as above and the sample was left to dry in air 146 prior to TEM characterisation. This sample preparation technique was previously reported to give good 147 quality of images for PLGA-PEG nanoparticles [39].

148

2.5. Small-Angle Neutron Scattering (SANS) study

PLGA-PEG nanoparticles were prepared as described above. Briefly, 10 mg of polymers were dissolved in 1 mL of organic solvent (acetone or DMSO). This solution was then added to 20 mL of D₂O dropwise under continuous stirring to form suspension of nanoparticles, which was then allowed to stir gently for an additional 20 min. Finally, 2 mL of aliquot was aspirated from the suspension and dialysed using a Spectra-Por[®] Float-A-lyzer[®] G2 dialysis membrane, with a molecular weight cut-off 3.5–5 kDa, against D₂O to remove residual solvent, filtered using 0.22 µm Minisart[®] syringe filters and stored in a fridge prior to SANS studies.

156 SANS experiments were performed at MLZ (Garching, Germany) on KWS-2 instrument [40]. 157 Measurements were made on a ³He tubes array detector (144 tubes, pixel size 8 mm) using a non-158 polarised, monochromatic (wavelength λ set by a velocity selector) incident neutron beam collimated 159 with rectangular apertures for two sample-to-detector distances, namely 2, 8, and 20 m ($\lambda = 0.6$ nm). With this setup, the investigated q-range was 0.015 nm⁻¹ to 4.6 nm⁻¹. In all cases, the two-dimensional 160 161 scattering patterns were isotropic and were azimuthally averaged, resulting in the dependence of the 162 scattered intensity $I_s(q)$ on the momentum transfer $q = 4\pi \sin\theta/\lambda$, where 2θ is the scattering angle. The 163 curves were corrected for background scattering from the empty cell and for detector efficiency. Hellma[®] Analytics Suprasil[®] 300 high precision quartz cells of 1 and 2 mm thickness were used for experiments. 164 165 SANS experiments were performed in D₂O solution. The D₂O solution was measured and properly 166 subtracted. The concentration of nanoparticles used in SANS measurements was 0.5 mg/mL.

167 **2.6.** SANS data fitting

168 The scattered intensity curves were fitted using the model of sphere with attached Gaussian chain 169 having self-avoiding walk statistics implemented in SASFit software [41] based on the model developed 170 by Pedersen et al. [42] (Fig. 1).

171 The scattering curves in D₂O could be fitted using the following function:

172
$$I(q) = P_{sgc}(q)S(q)$$
 (1)

173 We assume that S(q) = 1 due to low concentration of nanoparticles in solution, 1 mg/mL. The 174 overall scattering intensity of the sphere with attached Gaussian chain written as:

175
$$P_{sgc} = N_{agg}^2 \beta_{core}^2 P_{core}(q) + N_{agg} \beta_{brush}^2 P_{brush}(q) + 2N_{agg}^2 \beta_{core} \beta_{brush} S_{brush-core}(q) + N_{agg}(N_{agg} - 1)\beta_{brush}^2 S_{brush-brush}(q)$$
(2)

177 where
$$N_{agg}^2 \beta_{core}^2 P_{core}(q)$$
 is self-correlation term of the core; $N_{agg} \beta_{brush}^2 P_{brush}(q)$ is self-correlation
178 term of the chains; $2N_{agg}^2 \beta_{core} \beta_{brush} S_{brush-core}(q)$ is the cross-term between the core and chains and
179 $N_{agg}(N_{agg} - 1)\beta_{brush}^2 S_{brush-brush}(q)$ is the cross-term between different chains. N_{agg} is the
180 aggregation number of polymers forming the nanoparticle per surface area, $\beta_{brush} = V_{brush}(\eta_{brush} - \eta_{solv})$ and $\beta_{core} = V_{core}(\eta_{core} - \eta_{solv})$ are the excess scattering lengths of a block in the corona and in
182 the core, respectively. V_{brush} and V_{core} are the total volume of a block in the corona and in the core,
183 respectively. η_{brush} and η_{core} are the corresponding scattering length densities (SLDs). $P_{core}(q)$ is
184 scattering of spherical core

185
$$P_{core}(q, R_{core}) = 3 \frac{(\sin(qR_{core}) - qR_{core}\cos(qR_{core}))}{(qR_{core})^3}$$
(3)

186 The scattering intensity for the brush is given by:

187
$$P_{brush}(q, R_{gchain}) = 2 \frac{exp(-x) - 1 + x}{x^2}$$
 (4)

188 where $x = R_{gchain}^2 q^2$; R_{gchain} is the gyration radius of a polymer chain.

189 The contribution of cross term between core and chains which form brush of wormlike micelle is190 calculated using equation:

191
$$S_{brush-core}(q, R_{core}, R_{gchain}, d) = \psi(qR_{gchain})P_{core}(q, R_{core})\frac{\sin(q[R_{core}+dR_{gchain}])}{q[R_{core}+dR_{gchain}]}$$
(5)

192 where $\psi(qR_{gchain}) = \frac{1-exp(-x)}{x}$ is the form factor amplitude of the chain.

193 The contribution of cross term between chains is calculated using equation:

194
$$S_{brush-brush}(q, R_{core}, R_{gchain}, d) = \psi^2(qR_{gchain}) \left[\frac{sin(q[R_{core}+dR_{gchain}])}{q[R_{core}+dR_{gchain}]}\right]^2$$
(6)

195 where *d* is parameter that accounts for non-penetration of the chains into the core and should be 196 mimicked by $d \sim 1$ for $R_{core} \gg R_{gchain}$.

197 The model has the following fitting parameters: R_{core} – core radius; V_{core} – molecular volume of 198 single block unit in the micellar core; V_{brush} – molecular volume of single block unit in the micellar 199 corona; η_{core} – scattering length density of spherical core; η_{brush} – scattering length density of the block 200 unit in the corona; η_{solv} – scattering length density of solvent; R_{gchain} – gyration radius of polymer 201 chains in the corona; L – contour length of polymer chain, b – Kuhn segment length.

Excess scattering lengths of solvent and polymeric shell, V_{core} , V_{brush} , contour length of polymer chain, Kuhn segment length were known from literature data and polymer composition and were chosen to be fixed during the fitting procedure.

205 To account for nanoparticles polydispersity, a Schulz-Zimm distribution of R_{core} with 206 polydispersity parameter σ was included in the following way:

207
$$SZ = \frac{R_{core}^Z}{\Gamma(Z+1)} \left(\frac{Z+1}{\langle R_{core} \rangle}\right)^{Z+1} exp\left[-\frac{(Z+1)R_{core}}{\langle R_{core} \rangle}\right]$$
(7)

208 where
$$Z = \frac{1}{\sigma^2} - 1$$
 (8)

209 The gyration radius R_g of nanoparticles was calculated from Guinier regime to evaluate the overall 210 size of nanoparticles.

211 **2.7. Encapsulation efficiency and loading capacity**

Amicon[®] Ultra-0.5 Ultracel-3 centrifugal filter unit with a molecular weight cut-off 10 kDa was used in these experiments. Each centrifugal filter device was pre-rinsed with PBS (500 μ L) at 13,000 rpm (7558 × g) for 30 min prior to further use. The dispersion of PLGA-PEG nanoparticles (500 μ L) was placed in an ultrafiltration tube and centrifuged at 4 °C at 13,000 rpm (7558 × g) for 30 min. This loading 216 step was repeated twice. The filtrate was discarded and the retentate was washed with 250 µL of PBS by 217 further centrifugation at 4 °C at 13,000 rpm (7558 × g) for 20 min. The filtrate was withdrawn again and 218 the fluorescein-loaded PLGA-PEG nanoparticles in the retentate were then mixed with 100 µL DMSO 219 (left for 6 h in a fridge to dissolve the nanoparticles and model drug) and spun at 4 °C at 13,000 rpm 220 $(7558 \times g)$ for 10 min. The amount of free fluorescein in the supernatant was quantified using a Varian Cary Eclipse fluorescence spectrophotometer at $\lambda_{excitation}$ and $\lambda_{emission} = 460$ and 513 nm, respectively, 221 222 and the encapsulation efficiency (EE%) and loading capacity (LC%) were determined using the 223 following formulae:

$$224 \qquad EE\% = \frac{c}{c_i} \times 100 \tag{9}$$

$$225 LC\% = \frac{C}{Total \, weight \, of \, NPs} \times 100 (10)$$

where *C* is the amount of fluorescein encapsulated in the nanoparticles (NPs), and C_i is the initial amount of fluorescein. A standard curve was generated by plotting the fluorescence intensities from different concentrations of the model drug and used to calculate EE% and LC% can be found in Supplementary Information (Fig. S1).

230 **2.8.** Toxicology: slug mucosal irritation test

The slug mucosal irritation test (SMIT) was carried out according to our previously published report [43]. *Arion lusitanicus* slugs were collected locally in Harris Garden (Reading, UK) and were housed in specially designed plastic containers and fed with lettuce, cabbage, carrots and cucumber. Each slug's body lining was carefully examined and only slugs showing no evidence of macroscopic injuries with clear tubercles and a foot surface were used for testing purposes. Slugs weighing between 15 and 23 g were isolated from the culture and were kept individually in 1.5 L glass beakers lined with a paper 237 towel soaked with 20 mL of PBS solution and left at room temperature for 48 h before the start of an 238 experiment. All beakers were covered with a cling film pierced with tiny holes in order to allow air 239 exchange. Each slug was individually weighed before the experiment and then placed in 90 mm Petri dishes lined with Whatman[™] filter paper moistened with either positive/negative controls (2 mL of 1% 240 BAC prepared in PBS and 2 mL of PBS solution, respectively) or 2 mL of each test materials (PEG, 241 242 PEG-Mal and MHA) with the following concentrations: 0.00003; 0.0003; 0.003 and 0.03 mmol prepared 243 in PBS. After 60 min contact period slugs were taken out, rinsed with 10 mL of PBS, gently wiped with 244 the paper towel and then reweighed. The percentage of mucus production (MP%) was estimated as a slug 245 body weight loss and evaluated using the following equation:

246
$$MP\% = \frac{(m_b - m_a)}{m_b} \times 100$$
 (11)

where m_b and m_a are the weights of a slug before and after experiment, respectively. Each experiment was repeated 7 times using different slugs and the results were evaluated statistically, calculating the mean \pm standard deviation values.

250

2.9. Preparation of artificial urine solution

Artificial urine solution was prepared according to the previously reported protocol [44]. Briefly, the following components were dissolved in deionised water by stirring overnight at room temperature, before making the total volume to 2000 mL: urea (24.27 g), uric acid (0.34 g), creatinine (0.90 g), sodium citrate dihydrate (Na₃C₆H₅O₇ \cdot 2H₂O, 2.97 g), sodium chloride (NaCl, 6.34 g), potassium chloride (KCl, 4.50 g), ammonium chloride (NH₄Cl, 1.61 g), calcium chloride dihydrate (CaCl₂ \cdot 2H₂O, 0.89 g), magnesium sulfate heptahydrate (MgSO₄ \cdot 7H₂O, 1.00 g), sodium bicarbonate (NaHCO₃, 0.34 g), sodium oxalate (Na₂C₂O₄, 0.03 g), sodium sulphate (Na₂SO₄, 2.58 g), sodium phosphate monobasic monohydrate 258 (NaH₂PO₄ · H₂O, 1.00 g), and sodium phosphate dibasic (Na₂HPO₄, 0.11 g). The artificial urine solution

259 (pH 6.40) was kept at 37 °C throughout the experiments.

260 **2.10.** *In vitro* retention studies on lamb urinary bladder mucosa

261 The retention of PLGA-PEG nanoparticles on lamb urinary bladder tissues in vitro was determined 262 using a protocol previously described by our group with minor modifications [29]. Lamb bladder tissues were received from P.C. Turner Abattoirs (Farnborough, UK) immediately after animal slaughter, 263 264 packed, frozen and transported in an insulated plastic container. The tissues were subsequently thawed 265 upon arrival and carefully excised to yield approximately 2×3 cm sections, avoiding contact with the 266 internal mucosa, which were then used in the experiments. The dissected bladder tissue was mounted on 267 a glass slide with mucosal side facing upward and rinsed with 3 mL of artificial urine (AU; pH 6.40) 268 solution. Experiments were performed with the bladder tissues maintained at 37 °C in an incubator. 269 Aliquots (200 µL) from fluorescein-loaded PLGA-PEG nanoparticle stock solutions were withdrawn and 270 deposited onto a mucosal surface and rinsed with AU at a constant flow rate of 2 mL/min using a syringe 271 pump (total washing time was 50 min). Fluorescence images of a bladder tissue were taken using Leica 272 MZ10F stereo-microscope (Leica Microsystems, UK) with Leica DFC3000G digital camera at 1.6× 273 magnification with 30 ms exposure time (gain $2.0\times$), fitted with a GFP filter. The microscopy images 274 were then analysed with ImageJ software by measuring the pixel intensity after each irrigation with AU. 275 The pixel intensity of the blank samples (bladder mucosa without test material) were subtracted from 276 each measurement and data are converted into numbers. All measurements were conducted in triplicate. 277 Evaluation of formulations retention on the mucosa *in vitro* was quantified through WO₅₀ values, 278 which represent the volume of a biological fluid necessary to wash out 50 % of a mucoadhesive excipient 279 from a substrate [45]. WO₅₀ values of test materials were calculated *via* extrapolation of the average 280 wash-off profiles to 50% using polynomial fitting (5th order) and Wolfram Alpha (a computational 281 knowledge engine).

2.11. Statistical analysis

Statistical analysis of data, i.e. mean values \pm standard deviations were calculated and assessed for significance using two-tailed Student's *t*-test and a one-way analysis of variance (ANOVA) followed by Bonferoni *post hoc* test using GraphPad Prism software (version 7.0), where *p* < 0.05 was fixed as the statistical significance criterion.

287 **3. Results and discussion**

288 **3.1.** Preparation and characterisation of nanoparticles

289 PLGA-PEG nanoparticles, with and without fluorescein, were formulated using single emulsion 290 method and precipitated from acetone and DMSO. The detailed preparation procedure of nanoparticles 291 is illustrated in Fig. 2. The average mean diameter of all PLGA-PEG nanoparticles precipitated from 292 DMSO remained $\sim 100 \pm 1$ nm on average regardless of the molecular weight of PEG molecular block 293 copolymers, whereas the nanoparticles precipitated from acetone displayed smaller values of 65 ± 1 nm 294 and 80 ± 1 nm for PLGA-PEG and PLGA-PEG-Mal, respectively. We believe that the difference in the 295 particle sizes might depend on the dielectric constant of organic solvent (acetone, $\varepsilon = 21$ and DMSO, ε 296 = 47) and their miscibility with water during formation of nanoparticles in aqueous phase [46]. It is also 297 interesting to compare our results with the study reported by Yang et al. [47], who prepared PLGA-PEG 298 nanoparticles from acetone, acetonitrile and tetrahydrofuran. They reported the solvent effect on the 299 particle size with formation of 154 ± 3 , 134 ± 2 and 186 ± 4 nm of nanoparticles from acetone, acetonitrile 300 and tetrahydrofuran, respectively. Our nanoparticles prepared from acetone are much smaller (65 ± 1 301 nm), which shows the strong influence of other factors, including individual block molecular weights 302 and particle preparation techniques.

All nanoparticles prepared in the present study showed negative zeta-potential greater than -21 mV and had low polydispersity of less than 0.20, indicating the presence of a homogeneous population with a narrow size distribution (Fig. 3). The physicochemical characteristics of PLGA-PEG nanoparticles are
 summarised in Table 1.

Fluorescein was used as a model drug to demonstrate the potential application of PLGA-PEG nanoparticles in drug delivery to urinary bladder. Fluorescein (partition coefficient, logP = 3.35, [48]) was loaded into the nanoparticles by first preparing the model drug solution in the organic solvent followed by dissolution of polymers and further nanoprecipitation in deionised water.

The size and morphology of nanoparticles were further confirmed by TEM analysis and microphotographs are displayed in Fig. 4. Uranyl acetate was used as a negative staining to achieve reasonable contrast. TEM analysis revealed the formation of homogeneous vehicles with well-dispersed spherically shaped core and shell structure of nanoparticles and the results are in good agreement with the data obtained by DLS measurements (Table 1).

316 **3.2.** Nanoparticle structure

317 Small-angle neutron scattering (SANS) was used to probe the nanoparticle architecture and 318 determine their molecular parameters. The use of SANS allows to get more information about small 319 particles compared to DLS method. The scattering intensity I(q) curves for all nanoparticle solutions are 320 presented in Fig. 5A and 5B. Several issues should be noted from the inspection of these scattering 321 curves. First, all curves have monotonous behaviour with q; no additional maxima are observed. It is a 322 typical manifestation of moderate or high polydispersity for compact objects. Second, all curves are 323 similar in the middle and high q ranges that implies similarity of all nanoparticles from inside 324 disregarding preparation way and used solvent. The only difference between the scattering curves is 325 visible in low q range that is probably related to the difference in the aggregation number. To have a 326 deeper information, the gyration radius values of nanoparticles in solution were calculated using Guinier 327 approximation (Table 2). Comparison of gyration and hydrodynamic radii reveals that these two 328 parameters are clearly correlated. In agreement with DLS data, the gyration radius value for PLGA-PEG 329 and PLGA-PEG-Mal nanoparticles precipitated from DMSO is nearly the same and insensitive to the 330 PEG molecular weight to the presence of maleimide groups (Table 2). In contrast, the gyration radius 331 value of nanoparticles precipitated from acetone is higher for longer length of a PEG chain. The ratio of 332 gyration and hydrodynamic radii R_g/R_h have been known as the ρ parameter that is sensitive to the 333 architecture of nano-objects. It provides model-independent clue on spatial arrangement of a scattering 334 object [49–53], its theoretical value is known for some simple models such as a hard sphere ($\rho =$ 335 0.775), Gaussian chain in Θ -solvent ($\rho = 1.5$), long rods ($\rho > 2.0$). The ρ parameter value calculated 336 for PLGA-PEG and PLGA-PEG-Mal nanoparticles precipitated from DMSO undoubtedly pointing out 337 on a spherical symmetry and compact structure in agreement with TEM results presented above. The 338 change from DMSO to acetone results in the formation of nanoparticles with more loose structure since 339 they have higher ρ parameter value. Increasing of PEG molecular weight leads to increase in ρ value 340 highlighting the enhanced branching structure for 5 kDa PEG nanoparticles made from acetone. We have 341 to mention here that some of these systems have ρ value that is below the lowest possible theoretical 342 limit, 0.775. Nevertheless, low values were already reported in a variety of publications. The ρ parameter 343 fluctuates around 0.8, an average value for all types of nanoparticles justifying the choice of the fitting 344 model described in Experimental Section.

The scattering curves obtained for the D_2O solutions can be well fitted with the "sphere with attached Gaussian chain having self-avoiding walk statistics" model, assuming a Schulz-Zimm distribution for core radius. The calculated structural parameters are presented in Table 2.

The obtained value of the core radii and shell thickness are in the range of 12–24 nm, which is in agreement with the R_h as observed in the DLS measurements and TEM. In all series of nanoparticles prepared by precipitation from acetone and DMSO, R_{gchain} increases with increase in PEG molecular weight (Table 2), whereas R_{core} is much less sensitive to PEG chain length.

352	Our results corroborate with SANS studies of PLGA-PEG based block copolymers published
353	previously [47,54–57] keeping in mind the difference in composition, molecular weights and methods of
354	preparation. For example, PEO-PLGA-PEO [55] and PLGA-PEG-PLGA [56] triblock copolymers were
355	investigated using SANS. Apart from the difference in composition, triblock vs diblock, the copolymers
356	reported in these papers were different on other important aspects. The molecular weight, Mn, of PLGA
357	block was much lower than the one in our case, 3,500 g/moL [55] and 1,170 g/moL [56], respectively.
358	In both cases solutions were prepared by direct dissolving in D ₂ O in contrast with solvent exchange
359	method exploited in the present paper. Additionally, structure factor was involved in the fitting procedure
360	since the triblock copolymer solution were in semi-diluted regime, 24 and 20 wt.% for PEO-PLGA-PEO
361	and PLGA-PEG-PLGA, respectively. Applying the Percus-Yevick (PY) hard-sphere model to describe
362	the structure factor and Global Indirect Fourier Transformation (GIFT) to describe the form factor of the
363	micelles composed of PEO-PLGA-PEO at 30 °C, the authors obtained the following values for the radii
364	of a core and shell, 5.9 and 2.5 nm, respectively [55]. The presence of a shell was also reported by
365	Khorshid et al for flower-like micelles composed by PLGA-PEG-PLGA triblock copolymers [56]. SANS
366	method successfully disseminates the internal structure of nanoparticles. The SANS experiments give a
367	clear evidence of asymmetric ellipsoid nanoparticles for the copolymer with the PEG block ($Mn = 1,000$
368	g/moL), whereas spherical micelles with core-shell topology is observed for the polymer with longer
369	PEG central block ($Mn = 1,500 \text{ g/moL}$). The core-shell cylinder and spherical shell models were utilised
370	to fit the SANS data [56]. Unlike the PEO-PLGA-PEO system, both PLGA-PEG-PLGA copolymers
371	were studied not only in semi-diluted but also for diluted concentration, 1 wt.%. The core and shell radii
372	for PLGA ₁₁₇₀ -PEG ₁₅₀₀ -PLGA ₁₁₇₀ were 5.0 nm and these values are much lower in comparison with the
373	data reported in our manuscript, R _{core} and R _{gchain} , Table 2, that is not surprising keeping in mind much
374	higher molecular weights for PLGA and PEG of our copolymers.
375	Interesting contrast variation SANS study was performed for laponite/PEG1.0k-PLGA0.8k and

laponite/PEG1.0k-PLGA1.6k nanocomposites in a broad range of D₂O/H₂O mixture concentrations [57].

377 It was found that for 66 % of D₂O, the scattering from laponite is matched to the scattering of solvent. 378 The combination of core-shell spherical model in combination with Debay form factor was used for the 379 fitting the scattering profile from laponite free nanoparticles made of PEG-PLGA copolymers. The radius 380 of a core and the micelles was found 1.6 and 4.7 nm, respectively, giving the shell thickness value to be 381 of 3.1 nm [57]. We note here that the model used in our work is very close to the one reported in [57]. 382 Two SANS studies that are the most relevant to our paper deal with nanoparticles composed from PLGA-383 PEG [47] and PLA-PEG [54] diblock copolymers. In both papers, nanoparticles were prepared by solvent 384 exchange method. The spherical model with a polydisperse core of constant scattering density and 385 diffusive shell was applied for the fitting of PLA-PEG copolymers [54]. The fitting data reported for the 386 acetone as the organic solvent and copolymer with similar composition PLA_{15600} -PEG₅₀₀₀ are in perfect 387 agreement with our results for PLGA_{20K}-PEG_{5K} (Table 2). The mean core radius of the nanoparticles 388 made of PLA₁₅₆₀₀-PEG₅₀₀₀ is 11 nm, which correlates with our results, 12 nm. The Schultz-Zimm 389 poldispersity values are almost identical, 0.27 [54] vs 0.21 in our study. The thickness of the PEG shell 390 of 6.7 nm for PLA₁₅₆₀₀-PEG₅₀₀₀ also agrees well with our data for PLGA_{20K}-PEG_{5K} that was found to be 391 6.9 nm.

392 Surprisingly, the similar systems measured recently show clearly distinctive results [47]. The 393 PLGA-PEG nanoparticles prepared by solvent exchange method presumably composed from micelles 394 that form a fractal structure inside of a nanoparticle. One of the plausible explanations could be the 395 existence of some residual reactive groups on PLGA-PEG copolymers reported in [47]. Such reactive 396 groups might form bridges between PLGA-PEG micelles.

The choice of the solvent used for precipitation has the greatest impact on nanoparticles structure. Interestingly, nanoparticles dissolved and precipitated from acetone have not only a smaller core but also lower R_{gchain} value in comparison with the NPs precipitated from DMSO. This is a rather unpredicted result that might indicate a different local structure of the interface between PLGA core and PEG brush and different conformation of PEG chains. Indeed, the gyration radius of a PEG chain is twice lower for 402 NPs precipitated from acetone. Such striking difference could only be explained by compaction of PEG 403 chains on the surface of nanoparticles precipitated from acetone and, in reverse, fully stretched PEG 404 conformation in case of NPs made from DMSO. This hypothesis is indirectly supported by another 405 peculiar feature observed from the SANS results fitting: the presence of maleimide terminal groups increases the R_{gchain} for DMSO series, and in reverse, decreases R_{gchain} for NPs precipitated from 406 407 acetone (Table 2). We hypothesize that NPs prepared from DMSO have a narrow interface between 408 PLGA and PEG blocks, whereas precipitation from acetone somehow facilitates the formation of the 409 broad interface layer where PLGA and PEG coexist. Inevitably, bulky maleimide groups attached to the 410 dangling PEG chains increase the gyration radius of PEG for NPs precipitated from DMSO. For NPs 411 precipitated from acetone we might expect that some of Mal groups, due to hydrophobic nature of 412 maleimide, will have tendency to incorporate into smooth PLGA-PEG interface (see inserts in Fig. 5). 413 Provided that the nanoparticles precipitated from DMSO have the greatest presence of active maleimide 414 groups on their surface, all subsequent experiments were performed with these samples.

415 **3.3.** Mucosal irritancy

The information about the biocompatibility and toxicological characteristics of maleimidecontaining materials is currently lacking in the literature. Previously, the biocompatibility of polysaccharides functionalised with maleimide groups was evaluated only by Shtenberg et al. [30] using normal human dermal fibroblasts and by Sahatsapan et al. [31] using human gingival fibroblast cells.

The slug mucosal irritation test (SMIT) was developed by Adriaens et al. [58,59] to evaluate the mucosal irritancy potential of different formulations and active ingredients. It uses terrestrial slug species, which are considered to have limited sentience and so are not protected by regulations covering animal experiments [58]. Normally, slugs release mucus to aid their locomotion. They also produce mucus and lose body weight when in contact with irritating substrates. When their mucosal tissue is damaged the slugs release additional proteins and enzymes. This indication allows for quantifiable outcomes as for 426 irritants to be classified as non-irritating, mild or severely irritating. Generally, mild irritants cause an
427 increase in mucus production, whereas severe irritants result in tissue erosion and more mucus release in
428 addition to increased production [60].

Previously we reported the use of SMIT for assessing mucosal irritancy of 2-429 430 hydroxyethylmethacrylate and 2-hydroxyethylacrylate based random copolymers of different 431 compositions as well as blend films based on poly(acrylic acid) and methylcellulose using *Limax flavus* 432 and Arion lusitanicus slugs [43,61]. In the present work, we have adopted the same methodology and 433 used Arion lusitanicus slugs to evaluate the ability of model compounds PEG, PEG-Mal and 6-434 maleimidohexanoic acid (MHA) to cause mucosal irritation. Fig. 6 presents the results on mucus 435 production by slugs exposed to filter paper surfaces moistened with solutions of PEG, PEG-Mal and 436 MHA of various concentrations prepared in PBS as well as positive and negative controls. In experiments 437 with 1% solution of BAC in PBS (pH 7.50), used as a positive control, slugs experienced a severe 438 discomfort, producing approximately $38 \pm 7\%$ of yellow mucus, whereas slugs exposed to PBS (used as 439 a negative control, pH 7.74) did show a low level of mucus production of $5 \pm 1\%$. These data are in good 440 agreement with our previous studies [43,61]. A significant variability of the data obtained from 441 experiments with positive control is explained by slugs' increased activity and tendency to escape a 442 contact with an irritant chemical. In all experiments with negative control and polymeric excipients slugs 443 secreted colourless mucus, which is the first demonstration of their reasonably good biocompatibility.

The concentration of test materials of 0.0003 mmol, used to prepare PLGA-PEG nanoparticles in dispersion, was chosen as a reference for the preparation of liquid formulations with model maleimidecontaining compounds (MHA and PEG-Mal). Filter paper soaked with 0.03 mmol MHA (pH 4.34) displayed significantly higher irritancy (p < 0.001) compared to PEG-Mal (0.03 mmol; MP 6 ± 2%; pH 6.92) with the level of mucus production reaching 21 ± 7% and confirming the ability of MHA to irritate mucosal epithelia due to, mainly, its acidic nature (Fig. 6). Additionally, slugs exposed to positive control exhibited an extreme discomfort (p < 0.0001) compared to slugs in response to contact with 0.0003 mmol 451 PEG-Mal. However, filter paper soaked with increasing concentrations of PEG and PEG-Mal 452 demonstrated low irritation potential as no significant differences (p > 0.5) were observed between these 453 materials and the negative control. Fig. S2 and Fig. S3 in Supplementary Information provide the detailed 454 schematic illustration of SMIT test and the photographs of mucus production by Arion lusitanicus slugs exposed to various test chemicals, respectively. Safety, non-toxicity, and biocompatibility of PEG-Mal 455 456 allows us to conclude that PLGA-PEG-Mal nanoparticles should not cause irritation in the bladder lining. 457 The non-irritant nature of maleimide-functionalised materials established in this study is also in good agreement with the data reported by Shtenberg et al. [30], who reported that alginate modified with 458 459 maleimide-terminated PEG is non-toxic to normal human dermal fibroblasts. The maleimide-460 functionalised chitosan was also reported by Sahatsapan et al. [31] to be non-toxic to gingival fibroblast 461 cells (HGF) up to 1000 μ g/mL of polymer in solution.

462 **3.4. Mucoadhesion studies**

The retention properties of fluorescein-loaded PLGA-PEG and PLGA-PEG-Mal nanoparticles on 463 464 lamb urinary bladder mucosa were evaluated using a flow-through method with fluorescent detection using the methodology described in our previously published paper [29]. Fig. 7 shows exemplary 465 466 fluorescent images of the retention of PLGA-PEG and PLGA-PEG-Mal nanoparticle dispersions on 467 urinary bladder mucosa irrigated with AU. After analysis of the fluorescent images using ImageJ 468 software, it was established that maleimide-functionalised PLGA_{20K}-PEG_{5K}-Mal and PLGA_{20K}-PEG_{3K}-469 Mal nanoparticles exhibited greater mucoadhesive properties compared to unmodified counterparts (p < p470 0.001), confirming that PLGA-PEG-Mal nanoparticles adhere well to the bladder mucosa by forming 471 covalent linkages with thiol groups present in mucin layer of the bladder epithelium (Fig. 8). Such 472 selective binding leads to increased urothelium cell uptake and potentially improved drug bioavailability 473 within the bladder wall. The nanoparticles remained on the bladder mucosa even after 50 min of washing 474 with a cumulative AU volume of 100 mL. This is in good agreement with our previous findings [28,29], therefore the results of retention study confirm the mucoadhesive properties of maleimide-functionalised
PLGA-PEG nanoparticles, which could also be used as potential mucoadhesive drug carriers in IDD to
urinary bladder.

478 Previously we have introduced a novel quantitative method of evaluating and comparing the 479 retention efficacy of liquid formulations on mucosal membranes through the use of WO_{50} values, which 480 represent the volume of a biological fluid necessary to wash out 50 % of the mucoadhesive test material 481 from a substrate [45]. In this study, we employed the same method and calculated WO_{50} values by 482 analysing individual wash-off profiles for each nanoparticle suspensions and the results are presented in 483 Table 1. By comparing these values for different PLGA-PEG nanoparticles used in this study, it is clear that PLGA_{20K}-PEG_{5K}-Mal have greater retention on lamb bladder mucosa (WO₅₀ = 15 mL, $R^2 = 1$) 484 compared to unmodified PLGA_{20K}-PEG_{5K} (WO₅₀ = 5 mL, R^2 = 0.9872). 485

486 **4.** Conclusions

Four different types of PLGA-PEG nanoparticles were prepared and evaluated in this study for their physicochemical characteristics and retention on urinary bladder mucosa. The nanoparticles decorated with maleimide functional groups demonstrated greater retention on the bladder mucosa *in vitro* due to their ability to form covalent linkages with thiol groups of glycoproteins expressed on the bladder epithelial membrane. The biocompatibility of PEG-Mal was confirmed by SMIT assay experiments.

The development of mucoadhesive drug delivery systems that could improve drug residence in the bladder will clearly be beneficial for the treatment of bladder cancer. However, all existing strategies to develop mucoadhesive materials do not provide dosage forms that could selectively bind to cancer cells without adhesion to healthy epithelial cells. The development of systems that could target cancer cells in the bladder is one of the challenges for future research and development in this area.

The maleimide-functionalised PLGA-PEG mucoadhesive nanoparticles developed in this work could potentially be considered as a platform technology that could be used for drug delivery not only to the bladder but also to other mucosal routes of drug administration. Further research will be focused on biodegradation of these nanoparticles and studies of anticancer drugs encapsulation and release.

502 Acknowledgements

The authors gratefully acknowledge the British Council Newton – Al-Farabi Partnership Programme, the Researcher Links Post-Doctoral Mobility Grant (No. 216046068) for financial support and for providing 2-years postdoctoral fellowship for Dr D.B. Kaldybekov at the University of Reading. The Chemical Analysis Facility (University of Reading) is thanked for access to a fluorescence spectrophotometer and TEM. Dr S.K. Filippov acknowledges the financial support of U.S.–Czech Republic Fulbright Commission. P.C. Turner Abattoirs (Farnborough, UK) is also acknowledged for providing lamb urinary bladders for experiments.

510 **Conflict of interest**

511 The authors have no conflicts of interest to disclose.

512 **Author contributions**

513 The manuscript was written through contributions of all authors. All authors have given approval
514 to the final version of the manuscript.

515 Appendix A. Supplementary material

Supplementary data associated with this article is available free of charge. It contains a standard
curve used to determine the amount of encapsulated fluorescein in the PLGA-PEG nanoparticles (Fig.
S1); detailed schematic illustration of SMIT test (Fig. S2) and the photographs of mucus production by *Arion lusitanicus* slugs in contact with test materials (Fig. S3).

520 Abbreviations

521	AU, artificial urine; BAC, benzalkonium chloride; BC, bladder cancer; D ₂ O, deuterium oxide;
522	DLS, dynamic light scattering; DMSO, dimethyl sulfoxide; EE%, encapsulation efficiency; IDD,
523	intravesical drug delivery; LC%, loading capacity; Mal, maleimide; MHA, 6-Maleimidohexanoic acid;
524	MP%, mucus production; NPs, nanoparticles; PBS, phosphate buffered saline; PDI, polydispersity index;
525	PEG, poly(ethylene glycol) methyl ether; PEG-Mal, methoxypolyethylene glycol maleimide; PLGA-
526	PEG, poly(lactide-co-glycolide)-block-polyethylene glycol); SANS, small-angle neutron scattering;
527	SMIT, slug mucosal irritation test; TEM, transmission electron microscopy; UA, uranyl acetate; WO ₅₀ ,
528	Wash Out 50%.

529 **ORCID ID of authors**

- 530 Daulet B. Kaldybekov: <u>https://orcid.org/0000-0002-7191-5465</u>
- 531 Vitaliy V. Khutoryanskiy: <u>https://orcid.org/0000-0002-7221-2630</u>

532 **References**

533	[1]	V. V. Khutoryanskiy, Mucoadhesive materials and drug delivery systems, John Wiley & Sons,
534		Ltd, Chichester, UK, 2014. doi:10.1002/9781118794203.
535	[2]	G. Prosperi-Porta, S. Kedzior, B. Muirhead, H. Sheardown, Phenylboronic-acid-based polymeric
536		micelles for mucoadhesive anterior segment ocular drug delivery, Biomacromolecules. 17 (2016)
537		1449–1457. doi:10.1021/acs.biomac.6b00054.
538	[3]	B. Sarmento, A. Ribeiro, F. Veiga, D. Ferreira, R. Neufeld, Oral bioavailability of insulin
539		contained in polysaccharide nanoparticles, Biomacromolecules. 8 (2007) 3054-3060.
540		doi:10.1021/bm0703923.
541	[4]	Y.G. Seo, D.W. Kim, W.H. Yeo, T. Ramasamy, Y.K. Oh, Y.J. Park, J.A. Kim, D.H. Oh, S.K. Ku,
542		J.K. Kim, C.S. Yong, J.O. Kim, H.G. Choi, Docetaxel-loaded thermosensitive and bioadhesive

- 543 nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect, Pharm. Res.
 544 30 (2013) 1860–1870. doi:10.1007/s11095-013-1029-0.
- 545 [5] C.M. Caramella, S. Rossi, F. Ferrari, M.C. Bonferoni, G. Sandri, Mucoadhesive and thermogelling
 546 systems for vaginal drug delivery, Adv. Drug Deliv. Rev. 92 (2015) 39–52.
 547 doi:10.1016/j.addr.2015.02.001.
- 548 [6] C. Rieger, D. Kunhardt, A. Kaufmann, D. Schendel, D. Huebner, K. Erdmann, S. Propping, M.P.
 549 Wirth, B. Schwenzer, S. Fuessel, S. Hampel, Characterization of different carbon nanotubes for
 550 the development of a mucoadhesive drug delivery system for intravesical treatment of bladder
 551 cancer, Int. J. Pharm. 479 (2015) 357–363. doi:10.1016/j.ijpharm.2015.01.017.
- M. Hornof, W. Weyenberg, A. Ludwig, A. Bernkop-Schnürch, Mucoadhesive ocular insert based
 on thiolated poly(acrylic acid): Development and in vivo evaluation in humans, J. Control.
 Release. 89 (2003) 419–428. doi:10.1016/S0168-3659(03)00135-4.
- J.F. Fangueiro, F. Veiga, A.M. Silva, E.B. Souto, Ocular drug delivery new strategies for
 targeting anterior and posterior segments of the eye, Curr. Pharm. Des. 22 (2016) 1135–1146.
 doi:http://dx.doi.org/10.2174/1381612822666151216145900.
- 558 [9] M. Kapoor, J.C. Cloyd, R.A. Siegel, A review of intranasal formulations for the treatment of 559 seizure emergencies, J. Control. Release. 237 (2016) 147–159. doi:10.1016/j.jconrel.2016.07.001.
- L. Kozlovskaya, M. Abou-Kaoud, D. Stepensky, Quantitative analysis of drug delivery to the brain
 via nasal route, J. Control. Release. 189 (2014) 133–140. doi:10.1016/j.jconrel.2014.06.053.
- 562 [11] C. Mugabe, Y. Matsui, A.I. So, M.E. Gleave, J.H.E. Baker, A.I. Minchinton, I. Manisali, R.
 563 Liggins, D.E. Brooks, H.M. Burt, In vivo evaluation of mucoadhesive nanoparticulate docetaxel
 564 for intravesical treatment of non-muscle-invasive bladder cancer, Clin. Cancer Res. 17 (2011)
 565 2788–2798. doi:10.1158/1078-0432.CCR-10-2981.
- [12] R.R. De Araújo Pereira, M.L. Bruschi, Vaginal mucoadhesive drug delivery systems, Drug Dev.
 Ind. Pharm. 38 (2012) 643–652. doi:10.3109/03639045.2011.623355.

- 568 [13] O.M. Kolawole, W.M. Lau, H. Mostafid, V. V. Khutoryanskiy, Advances in intravesical drug
 569 delivery systems to treat bladder cancer, Int. J. Pharm. 532 (2017) 105–117.
 570 doi:10.1016/J.IJPHARM.2017.08.120.
- 571 [14] A.R. Mackie, F.M. Goycoolea, B. Menchicchi, C.M. Caramella, F. Saporito, S. Lee, K.
 572 Stephansen, I.S. Chronakis, M. Hiorth, M. Adamczak, M. Waldner, H. Mørck Nielsen, L.
 573 Marcelloni, Innovative methods and applications in mucoadhesion research, Macromol. Biosci.
 574 17 (2017) 1600534. doi:10.1002/mabi.201600534.
- 575 [15] P. Tyagi, P.C. Wu, M. Chancellor, N. Yoshimura, L. Huang, Recent advances in intravesical
 576 drug/gene delivery, Mol. Pharm. 3 (2006) 369–379. doi:10.1021/mp060001j.
- 577 [16] S. GuhaSarkar, R. Banerjee, Intravesical drug delivery: Challenges, current status, opportunities 578 and novel strategies, J. Control. Release. 148 (2010) 147–159. doi:10.1016/j.jconrel.2010.08.031.
- 579 [17] I.A. Sogias, A.C. Williams, V. V. Khutoryanskiy, Why is chitosan mucoadhesive?,
 580 Biomacromolecules. 9 (2008) 1837–1842. doi:10.1021/bm800276d.
- [18] E. Bilensoy, C. Sarisozen, G. Esendağli, A.L. Doğan, Y. Aktaş, M. Şen, N.A. Mungan,
 Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin
 C to bladder tumors, Int. J. Pharm. 371 (2009) 170–176. doi:10.1016/j.ijpharm.2008.12.015.
- 584 [19] H.T. Ta, C.R. Dass, D.E. Dunstan, Injectable chitosan hydrogels for localised cancer therapy, J.
 585 Control. Release. 126 (2008) 205–216. doi:10.1016/j.jconrel.2007.11.018.
- 586 [20] I. Bravo-Osuna, M. Noiray, E. Briand, A.M. Woodward, P. Argüeso, I.T.M. Martínez, R. Herrero-
- 587 Vanrell, G. Ponchel, Interfacial interaction between transmembrane ocular mucins and adhesive
- 588 polymers and dendrimers analyzed by surface plasmon resonance, Pharm. Res. 29 (2012) 2329–
- 589 2340. doi:10.1007/s11095-012-0761-1.
- M. Burjak, M. Bogataj, M. Velnar, I. Grabnar, A. Mrhar, The study of drug release from
 microspheres adhered on pig vesical mucosa, Int. J. Pharm. 224 (2001) 123–130.
 doi:10.1016/S0378-5173(01)00748-7.

- 593 [22] A. Bernkop-Schnürch, Thiomers: The next generation of mucoadhesive polymers, Adv. Drug
 594 Deliv. Rev. 57 (2005) 1569–1582. doi:10.1016/j.addr.2005.07.002.
- A. Bernkop-Schnürch, D. Guggi, Y. Pinter, Thiolated chitosans: Development and in vitro
 evaluation of a mucoadhesive, permeation enhancing oral drug delivery system, J. Control.
 Release. 94 (2004) 177–186. doi:10.1016/j.jconrel.2003.10.005.
- 598 [24] T. Schmitz, V. Grabovac, T.F. Palmberger, M.H. Hoffer, A. Bernkop-Schnürch, Synthesis and
 599 characterization of a chitosan-N-acetyl cysteine conjugate, Int. J. Pharm. 347 (2008) 79–85.
 600 doi:10.1016/j.ijpharm.2007.06.040.
- J. Iqbal, G. Shahnaz, S. Dünnhaupt, C. Müller, F. Hintzen, A. Bernkop-Schnürch, Preactivated
 thiomers as mucoadhesive polymers for drug delivery, Biomaterials. 33 (2012) 1528–1535.
 doi:10.1016/j.biomaterials.2011.10.021.
- J. Barthelmes, G. Perera, J. Hombach, S. Dünnhaupt, A. Bernkop-Schnürch, Development of a mucoadhesive nanoparticulate drug delivery system for a targeted drug release in the bladder, Int.
 J. Pharm. 416 (2011) 339–345. doi:10.1016/j.ijpharm.2011.06.033.
- [27] N. Denora, A. Lopedota, M. Perrone, V. Laquintana, R.M. Iacobazzi, A. Milella, E. Fanizza, N.
 Depalo, A. Cutrignelli, A. Lopalco, M. Franco, Spray-dried mucoadhesives for intravesical drug
 delivery using N-acetylcysteine- and glutathione-glycol chitosan conjugates, Acta Biomater. 43
 (2016) 170–184. doi:10.1016/j.actbio.2016.07.025.
- [28] P. Tonglairoum, R.P. Brannigan, P. Opanasopit, V. V. Khutoryanskiy, Maleimide-bearing
 nanogels as novel mucoadhesive materials for drug delivery, J. Mater. Chem. B. 4 (2016) 6581–
 6587. doi:10.1039/C6TB02124G.
- 614 [29] D.B. Kaldybekov, P. Tonglairoum, P. Opanasopit, V. V. Khutoryanskiy, Mucoadhesive
 615 maleimide-functionalised liposomes for drug delivery to urinary bladder, Eur. J. Pharm. Sci. 111
 616 (2018) 83–90. doi:10.1016/j.ejps.2017.09.039.
- 617 [30] Y. Shtenberg, M. Goldfeder, A. Schroeder, H. Bianco-Peled, Alginate modified with maleimide-


- 618 terminated PEG as drug carriers with enhanced mucoadhesion, Carbohydr. Polym. 175 (2017)
 619 337–346. doi:10.1016/j.carbpol.2017.07.076.
- [31] N. Sahatsapan, T. Rojanarata, T. Ngawhirunpat, P. Opanasopit, P. Tonglairoum, 6Maleimidohexanoic acid-grafted chitosan: A new generation mucoadhesive polymer, Carbohydr.
 Polym. 202 (2018) 258–264. doi:https://doi.org/10.1016/j.carbpol.2018.08.119.
- [32] Y. Xu, C.S. Kim, D.M. Saylor, D. Koo, Polymer degradation and drug delivery in PLGA-based
 drug–polymer applications: A review of experiments and theories, J. Biomed. Mater. Res. Part
 B Appl. Biomater. 105 (2017) 1692–1716. doi:10.1002/jbm.b.33648.
- [33] C. Jin, N. Qian, W. Zhao, W. Yang, L. Bai, H. Wu, M. Wang, W. Song, K. Dou, Improved
 therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18
 F(ab')2for hepatocellular carcinoma, Biomacromolecules. 11 (2010) 2422–2431.
 doi:10.1021/bm1005992.
- K. Zhang, X. Tang, J. Zhang, W. Lu, X. Lin, Y. Zhang, B. Tian, H. Yang, H. He, PEG-PLGA
 copolymers: Their structure and structure-influenced drug delivery applications, J. Control.
 Release. 183 (2014) 77–86. doi:10.1016/j.jconrel.2014.03.026.
- [35] U. Bazylińska, Rationally designed double emulsion process for co-encapsulation of hybrid cargo
 in stealth nanocarriers, Colloids Surfaces A Physicochem. Eng. Asp. 532 (2017) 476–482.
 doi:10.1016/j.colsurfa.2017.04.027.
- [36] Y. Pei, M.F. Mohamed, M.N. Seleem, Y. Yeo, Particle engineering for intracellular delivery of
 vancomycin to methicillin-resistant Staphylococcus aureus (MRSA)-infected macrophages, J.
 Control. Release. 267 (2017) 133–143. doi:10.1016/j.jconrel.2017.08.007.
- [37] A.S. Wadajkar, J.G. Dancy, N.B. Roberts, N.P. Connolly, D.K. Strickland, J.A. Winkles, G.F.
 Woodworth, A.J. Kim, Decreased non-specific adhesivity, receptor targeted (DART)
 nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive
 gliomas, J. Control. Release. 267 (2017) 144–153. doi:10.1016/j.jconrel.2017.09.006.

- [38] L. Zhang, Y. Shi, Y. Song, X. Sun, X. Zhang, K. Sun, Y. Li, The use of low molecular weight
 protamine to enhance oral absorption of exenatide, Int. J. Pharm. 547 (2018) 265–273.
 doi:https://doi.org/10.1016/j.ijpharm.2018.05.055.
- B. Zhang, P. Sai Lung, S. Zhao, Z. Chu, W. Chrzanowski, Q. Li, Shape dependent cytotoxicity of
 PLGA-PEG nanoparticles on human cells, Sci. Rep. 7 (2017) 7315. doi:10.1038/s41598-01707588-9.
- [40] A. Radulescu, N.K. Szekely, M.-S. Appavou, KWS-2: Small angle scattering diffractometer, J.
 Large-Scale Res. Facil. JLSRF. 1 (2015) A29. doi:10.17815/jlsrf-1-27.
- [41] I. Breßler, J. Kohlbrecher, A.F. Thünemann, SASfit: A tool for small-angle scattering data
 analysis using a library of analytical expressions, J. Appl. Crystallogr. 48 (2015) 1587–1598.
 doi:10.1107/S1600576715016544.
- [42] J.S. Pedersen, M.C. Gerstenberg, The structure of P85 Pluronic block copolymer micelles
 determined by small-angle neutron scattering, Colloids Surfaces A Physicochem. Eng. Asp. 213
 (2003) 175–187. doi:10.1016/S0927-7757(02)00511-3.
- 657 [43] O. V. Khutoryanskaya, P.W.J. Morrison, S.K. Seilkhanov, M.N. Mussin, E.K. Ozhmukhametova,
- T.K. Rakhypbekov, V. V. Khutoryanskiy, Hydrogen-bonded complexes and blends of
 poly(acrylic acid) and methylcellulose: Nanoparticles and mucoadhesive films for ocular delivery
 of riboflavin, Macromol. Biosci. 14 (2014) 225–234. doi:10.1002/mabi.201300313.
- [44] S. Chutipongtanate, V. Thongboonkerd, Systematic comparisons of artificial urine formulas for in
 vitro cellular study, Anal. Biochem. 402 (2010) 110–112. doi:10.1016/j.ab.2010.03.031.
- [45] E.A. Mun, A.C. Williams, V. V. Khutoryanskiy, Adhesion of thiolated silica nanoparticles to
 urinary bladder mucosa: Effects of PEGylation, thiol content and particle size, Int. J. Pharm. 512
 (2016) 32–38. doi:10.1016/j.ijpharm.2016.08.026.
- 666 [46] A.I. Vogel, B.S. Furniss, Vogel's textbook of practical organic chemistry, Longman, Harlow,
 667 Essex, England, 1989. https://books.google.kz/books?id=2eQPAQAAMAAJ.


- [47] B. Yang, J.P. Lowe, R. Schweins, K.J. Edler, Small angle neutron scattering studies on the internal
 structure of poly(lactide-co-glycolide)-block-poly(ethylene glycol) nanoparticles as drug delivery
 vehicles, Biomacromolecules. 16 (2015) 457–464. doi:10.1021/bm501519u.
- 671 [48] J.H. Lass, Advances in Corneal Research: Selected Transactions of the World Congress on the 672 Cornea IV, Springer & **Business** Media, MA. 1998. Science Boston, 673 https://books.google.kz/books?id=7wGH80U8tUIC.
- [49] S. Bantle, M. Schmidt, W. Burchard, Simultaneous static and dynamic light scattering,
 Macromolecules. 15 (1982) 1604–1609. doi:10.1021/ma00234a028.
- [50] W. Burchard, Static and dynamic light scattering from branched polymers and biopolymers, Light
 Scatt. from Polym. Adv. Polym. Sci. 48 (1983) 1–124. doi:10.1007/3-540-12030-0_1.
- [51] W. Brown, Light scattering: Principles and development, Clarendon Press, Oxford, England,
 1996. https://books.google.co.uk/books?id=RsNQGIIEbpwC.
- [52] D. Gromadzki, S. Filippov, M. Netopilík, R. Makuška, A. Jigounov, J. Pleštil, J. Horský, P.
 Štěpánek, Combination of "living" nitroxide-mediated and photoiniferter-induced "grafting from"
 free-radical polymerizations: From branched copolymers to unimolecular micelles and microgels,
 Eur. Polym. J. 45 (2009) 1748–1758. doi:10.1016/j.eurpolymj.2009.02.022.
- M. Hruby, C. Konak, J. Kucka, M. Vetrik, S.K. Filippov, D. Vetvicka, H. Mackova, G. Karlsson,
 K. Edwards, B. Rihova, K. Ulbrich, Thermoresponsive, hydrolytically degradable polymer
 micelles intended for radionuclide delivery, Macromol. Biosci. 9 (2009) 1016–1027.
 doi:10.1002/mabi.200900083.
- T. Riley, C.R. Heald, S. Stolnik, M.C. Garnett, L. Illum, S.S. Davis, S.M. King, R.K. Heenan,
 S.C. Purkiss, R.J. Barlow, P.R. Gellert, C. Washington, Core–shell structure of PLA–PEG
 nanoparticles used for drug delivery, Langmuir. 19 (2003) 8428–8435. doi:10.1021/la020911h.
- [55] M.J. Park, K. Char, Gelation of PEO–PLGA–PEO triblock copolymers induced by macroscopic
 phase separation, Langmuir. 20 (2004) 2456–2465. doi:10.1021/la035573e.

693	[56]	N.K. Khorsh	nid, K	. Zhu, K.D.	Knudsen, S.	Bekhradnia, S	.A. Sande,	B. Ny	yström, No	vel structural
694		changes duri	ing te	mperature-i	nduced self-a	assembling and	l gelation o	of PLC	GA-PEG-P	LGA triblock
695		copolymer	in	aqueous	solutions,	Macromol.	Biosci.	16	(2016)	1838–1852.
696		doi:10.1002/	/mabi	.201600277	•					


- 697 [57] T. Maeda, M. Kitagawa, A. Hotta, S. Koizumi, Thermo-responsive nanocomposite hydrogels
 698 based on PEG-b-PLGA diblock copolymer and laponite, Polymers (Basel). 11 (2019) 250.
 699 doi:10.3390/polym11020250.
- E. Adriaens, J.P. Remon, Gastropods as an evaluation tool for screening the irritating potency of
 absorption enhancers and drugs, Pharm. Res. 16 (1999) 1240–1244.
 doi:10.1023/A:1014801714590.
- [59] E. Adriaens, K. Dierckens, T.G.M. Bauters, H.J. Nelis, F. Van Goethem, P. Vanparys, J.P. Remon,
 The mucosal toxicity of different benzalkonium chloride analogues evaluated with an alternative
 test using slugs, Pharm. Res. 18 (2001) 937–942. doi:10.1023/A:1010928025753.
- J. Lenoir, C. Bachert, J.P. Remon, E. Adriaens, The Slug Mucosal Irritation (SMI) assay: A tool
 for the evaluation of nasal discomfort, Toxicol. Vitr. 27 (2013) 1954–1961.
 doi:10.1016/j.tiv.2013.06.018.
- [61] O. V. Khutoryanskaya, Z.A. Mayeva, G.A. Mun, V. V. Khutoryanskiy, Designing temperatureresponsive biocompatible copolymers and hydrogels based on 2-hydroxyethyl(meth)acrylates,
 Biomacromolecules. 9 (2008) 3353–3361. doi:10.1021/bm8006242.



Schematic illustration depicting the mechanism of enhanced mucoadhesion of PLGA-PEG-Mal
nanoparticles on urinary bladder mucosa.



- **Fig. 1.** The model used for the fitting of experimental SANS data.
- 722 (single column fitting image)



724 Fig. 2. Illustrative diagram depicting the preparation of PLGA-PEG nanoparticles with maleimide-

726 (2-column fitting image)

functionalised surface.





Fig. 3. Size distribution of PLGA-PEG (A) and PLGA-PEG-Mal (B) nanoparticles dissolved and
 precipitated from acetone and DMSO as determined by DLS.

730 (2-column fitting image)



- 731
- 732 Fig. 4. TEM microphotographs of PLGA-PEG-Mal NPs dissolved and precipitated from acetone (A) and
- 733 DMSO (B). Scale bars are 100 nm.
- 734 (single column fitting image)





Fig. 5. SANS curves for PLGA-PEG nanoparticles dissolved and precipitated from acetone (A) and
DMSO (B). Solid line is a fitting curve. Inserts: Proposed structures of nanoparticles.

738 (2-column fitting image)




739

740Fig. 6. Mucus production by Arion lusitanicus slugs in response to 60 min exposure to PEG, PEG-Mal741and MHA as well as positive (benzalkonium chloride – BAC) and negative (phosphate buffered saline –742PBS) controls. Data are expressed as mean \pm standard deviation (n = 7). Statistically significant743differences are given as: **** – p < 0.0001; *** – p < 0.001; ns – no significance.


744 (single column fitting image)







- 746 **Fig. 7.** Exemplar fluorescence images showing retention of PLGA-PEG nanoparticles on lamb urinary
- bladder mucosa washed with different volumes of AU. Scale bars are 2 mm.
- 748 (2-column fitting image)



749

Fig. 8. Percentage retention of PLGA-PEG nanoparticles on lamb urinary bladder mucosa after irrigating with different volumes of AU solution. Data are expressed as mean \pm standard deviation (n = 3). Statistically significant differences are given as: **** – p < 0.0001; *** – p < 0.001; ** – p < 0.01; ns – no significance.

754 (single column fitting image)

755 TABLES WITH CAPTIONS

756 **Table 1.** Physicochemical characteristics of PLGA-PEG nanoparticles.

Formulation	Solvent	Mean	PDI	Zeta-	EE%	LC%	WO ₅₀ (mL)*
	used in NPs	diameter		potential			
	preparation	(nm)		(mV)			
PLGA20K-PEG3K		94 ± 1	0.048	-20.8 ± 0.5	62.7 ± 3.6	3.1 ± 0.2	4; ($\mathbf{R}^2 = 0.9860$)
PLGA20K-PEG5K	DIMO	105 ± 1	0.070	-21.6 ± 0.4	63.8 ± 6.9	3.2 ± 0.4	5; $(R^2 = 0.9872)$
PLGA _{20K} -PEG _{3K} -Mal	DMSO	98 ± 1	0.060	-17.7 ± 0.6	60.0 ± 4.2	3.0 ± 0.2	6; $(\mathbf{R}^2 = 0.9931)$
PLGA _{20K} -PEG _{5K} -Mal		104 ± 1	0.067	-12.2 ± 0.5	55.0 ± 5.8	3.0 ± 0.3	15; $(\mathbf{R}^2 = 1)$
PLGA20K-PEG3K		64 ± 1	0.110	-8.1 ± 0.7	N/A	N/A	N/A
PLGA20K-PEG5K	Acetone	68 ± 1	0.248	-5.2 ± 0.6	N/A	N/A	N/A
PLGA20K-PEG3K-Mal		80 ± 1	0.094	-16.5 ± 0.6	N/A	N/A	N/A
PLGA20K-PEG5K-Mal		81 ± 1	0.206	-10.8 ± 0.8	N/A	N/A	N/A

758index; EE%, encapsulation efficiency; LC%, loading capacity; WO50, Wash Out 50% profile is a volume of artificial urine required to759wash out 50% liquid formulation; N/A, not applicable. *Polynomial fitting (5th order) was used to quantify WO50 values. Results are760given as mean \pm standard deviation (n =3).

761 (2-column fitting table)

PLGA20K-PEG5K 40.8 ± 1.5 0.78 15.4 ± 0.2 0.63 12.5 PLGA20K-PEG3K-Mal 35.7 ± 0.9 0.73 14.6 ± 0.1 0.31 14.6 ± 0.1 PLGA20K-PEG5K-Mal 35.5 ± 0.7 0.68 15.8 ± 0.2 0.20 16.6 PLGA20K-PEG3K 21.0 ± 0.8 0.66 10.2 ± 0.2 0.33 6.9	_{gchain} (nm)
DMSO 35.7 ± 0.9 0.73 14.6 ± 0.1 0.31 14.6 ± 0.1 PLGA _{20K} -PEG _{3K} -Mal 35.5 ± 0.7 0.68 15.8 ± 0.2 0.20 16.6 PLGA _{20K} -PEG _{3K} 21.0 ± 0.8 0.66 10.2 ± 0.2 0.33 6.9 PLGA _{20K} -PEG _{3K} 36.0 ± 0.5 1.06 12.0 ± 0.2 0.21 8.6	2.0 ± 0.1
PLGA20K-PEG3K-Mal 35.7 ± 0.9 0.73 14.6 ± 0.1 0.31 14.6 ± 0.1 PLGA20K-PEG5K-Mal 35.5 ± 0.7 0.68 15.8 ± 0.2 0.20 16.6 ± 0.1 PLGA20K-PEG3K 21.0 ± 0.8 0.66 10.2 ± 0.2 0.33 6.9 PLGA20K-PEG3K 36.0 ± 0.5 1.06 12.0 ± 0.2 0.21 8.6	2.1 ± 0.3
PLGA _{20K} -PEG _{3K} 21.0 \pm 0.8 0.66 10.2 \pm 0.2 0.33 6.9 PLGA _{20K} -PEG _{5K} 36.0 \pm 0.5 1.06 12.0 \pm 0.2 0.21 8.6	4.4 ± 0.2
PLGA _{20K} -PEG _{5K} 36.0 ± 0.5 1.06 12.0 ± 0.2 0.21 8.6	5.7 ± 0.3
	9 ± 0.1
Actor	6 ± 0.1
PLGA20K-PEG3K-Mal 30.0 ± 1.0 0.75 12.8 ± 0.1 0.50 4.1	1 ± 0.2
PLGA _{20K} -PEG _{5K} -Mal 33.0 ± 2.0 0.81 12.0 ± 0.1 0.24 8.3	3 ± 0.1

Table 2. Comparison of structural parameters obtained from samples PLGA-PEG nanoparticles in D₂O

763 DMSO, dimethyl sulfoxide; PLGA-PEG, poly(lactide-*co*-glycolide)-*block*-polyethylene glycol); Mal, maleimide; R_g , overall gyration

764 radius of a nanoparticle; R_{core} , core radius; σ , polydispersity parameter; R_{gchain} , gyration radius of a polymer chain in the corona.

765 (single column fitting table)